TY - JOUR T1 - Characterisation of the blood RNA host response underpinning severity in COVID-19 patients JF - medRxiv DO - 10.1101/2021.09.16.21263170 SP - 2021.09.16.21263170 AU - Heather Jackson AU - Irene Rivero Calle AU - Claire Broderick AU - Dominic Habgood-Coote AU - Giselle d’Souza AU - Samuel Nichols AU - Jose Gómez-Rial AU - Carmen Rivero-Velasco AU - Nuria Rodríguez-Núñez AU - Gema Barbeito-Castiñeiras AU - Hugo Pérez-Freixo AU - Manuel Barreiro-de Acosta AU - Aubrey J. Cunnington AU - Jethro A. Herberg AU - Victoria J. Wright AU - Alberto Gómez-Carballa AU - Antonio Salas AU - Mike Levin AU - Federico Martinon-Torres AU - Myrsini Kaforou AU - PERFORM consortium and GEN-COVID study group Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/21/2021.09.16.21263170.abstract N2 - Infection with SARS-CoV-2 has highly variable clinical manifestations, ranging from asymptomatic infection through to life-threatening disease. Host whole blood transcriptomics can offer unique insights into the biological processes underpinning infection and disease, as well as severity. We performed whole blood RNA Sequencing of individuals with varying degrees of COVID-19 severity. We used differential expression analysis and pathway enrichment analysis to explore how the blood transcriptome differs between individuals with mild, moderate, and severe COVID-19, performing pairwise comparisons between groups. Increasing COVID-19 severity was characterised by an abundance of inflammatory immune response genes and pathways, including many related to neutrophils and macrophages, in addition to an upregulation of immunoglobulin genes. Our insights into COVID-19 severity reveal the role of immune dysregulation in the progression to severe disease and highlight the need for further research exploring the interplay between SARS-CoV-2 and the inflammatory immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHJ receives support from the Wellcome Trust (4-Year PhD programme, grant number 215214/Z/19/Z). MK receives support from the Wellcome Trust (Sir Henry Wellcome Fellowship grant number 206508/Z/17/Z). CB receives support from the Wellcome Trust and NIHR Imperial BRC (4i Fellowship grant number RDA02). SN, GS, DH-C, JAH, AJC, MK, ML, ICR, FM-T, VW acknowledge funding for the EUCLIDS and PERFORM studies, funded by the European Union, grant numbers 668303 and 279185. JAH, ML and MK acknowledge support from the NIHR Imperial BRC. FM-T has received support for the present work from the Instituto de Salud Carlos III (Proyecto de Investigacion en Salud, Accion Estrategica en Salud): Fondo de Investigacion Sanitaria (FIS; PI070069/PI1000540/PI1601569/PI1901090) del plan nacional de I+D+I and fondos FEDER and Proyectos GaIN Rescata-Covid_IN845D 2020/23 (GAIN, Xunta de Galicia).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was approved by the Ethics Committee of Galicia by fast-track procedure on 18th March 2020 (CEIC Galicia, reg 2020/178)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGene counts and sample metadata are available on ArrayExpress under the accession E-MTAB-10926. ER -